RXi Pharma closes $11.5M equity offering

• RXi Pharmaceuticals (RXII) closes its public offering of units and warrants grossing $11.5M. Net proceeds of ~$10.4M will fund clinical trials and general corporate purposes. If it exercises its option to acquire MirImmune, the capital will fund the transaction and the development of its pipeline.
• Previously: RXi Pharma inks option agreement to acquire MirImmune (Oct. 12)